US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Nottingham stabbing victim Grace O'Malley
The parents of Nottingham stabbing victim Grace O'Malley-Kumar have backed calls for their daughter2024-05-01- The Center for Excellence in Quantum Information and Quantum Physics under the Chinese Academy of Sc2024-05-01
Guiyang's tourist appeal grows
Guizhou provincial capital becomes a major attraction to visitors who are relishing the variety of s2024-05-01Arrest warrant issued for man in fatal shooting of off
CHICAGO (AP) — An arrest warrant has been issued for a 22-year-old man in the fatal shooting of a Ch2024-05-01Workers' paychecks grew faster in the first quarter, a possible concern for the Fed
WASHINGTON (AP) — Pay and benefits for America’s workers grew more quickly in the first three months2024-05-01Donald Trump is running against Joe Biden. But he keeps bringing up another Democrat: Jimmy Carter
ATLANTA (AP) — As Donald Trump campaigns for a return to the White House, he often reaches back more2024-05-01
atest comment